• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Pakianathan Deepika

    5/29/25 4:13:39 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KPTI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    PAKIANATHAN DEEPIKA

    (Last) (First) (Middle)
    C/O KARYOPHARM THERAPEUTICS INC.
    85 WELLS AVE

    (Street)
    NEWTON MA 02459

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Karyopharm Therapeutics Inc. [ KPTI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/28/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Nonstatutory Stock Option (right to buy) $4.48(1) 05/28/2025 A 4,600(1) (2) 05/27/2035 Common Stock 4,600(1) $0 4,600(1) D
    Explanation of Responses:
    1. Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.
    2. This option vests as to 100% of the underlying shares on May 28, 2026.
    /s/ Nancy Smith, Attorney-in-Fact for Deepika Pakianathan 05/29/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KPTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KPTI

    DatePrice TargetRatingAnalyst
    1/19/2023$8.00Overweight
    Piper Sandler
    11/4/2022$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    3/8/2022$12.00 → $8.00Sector Perform
    RBC Capital
    3/2/2022$8.00 → $6.00Market Perform
    SVB Leerink
    2/9/2022$8.00Underweight → Neutral
    JP Morgan
    1/10/2022$6.00 → $8.00Market Perform
    SVB Leerink
    12/9/2021$8.00 → $9.00Sector Perform
    RBC Capital
    11/19/2021$27.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $KPTI
    SEC Filings

    See more
    • Karyopharm Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      5/29/25 4:28:22 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Karyopharm Therapeutics Inc.

      10-Q - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      5/12/25 4:14:43 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      5/12/25 4:06:37 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEWTON, Mass., July 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 666 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of June 30, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU award

      7/1/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm to Present at the Jefferies Global Healthcare Conference

      NEWTON, Mass., June 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 3:10 p.m. ET in New York, NY. A live webcast of the presentation along with accompanying slides can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event. About Karyopharm Therapeutics Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is

      6/3/25 8:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEWTON, Mass., June 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 566 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of May 31, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecuti

      6/2/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Su Zhen

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      5/29/25 4:15:13 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Pakianathan Deepika

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      5/29/25 4:13:39 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Oliger Christy J.

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      5/29/25 4:12:06 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Karyopharm Therapeutics with a new price target

      Piper Sandler initiated coverage of Karyopharm Therapeutics with a rating of Overweight and set a new price target of $8.00

      1/19/23 7:43:39 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Karyopharm Therapeutics from Sector Perform to Outperform and set a new price target of $10.00 from $7.00 previously

      11/4/22 7:23:40 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Karyopharm Therapeutics with a new price target

      RBC Capital reiterated coverage of Karyopharm Therapeutics with a rating of Sector Perform and set a new price target of $8.00 from $12.00 previously

      3/8/22 7:29:51 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care